Close
  Indian J Med Microbiol
 

Figure 1: Patient number 8: 177Lutetium-prostate-specific membrane antigen whole-body scans in anterior and posterior projection 24 h after injection of diagnostic dose of 185 MBq (a) and therapeutic dose of 6 GBq (b) of 177Lutetium-prostate-specific membrane antigen, which are comparable in showing multiple lymph node involvement in the abdomen and pelvic cavity. He is a 78-year-old man who had undergone radical prostatectomy and radiation therapy. He could not afford second-line hormone therapy (abiraterone and enzalutamide) and was not a suitable candidate for chemotherapy. The baseline prostate-specific antigen = 3.1 ng/ml declined to 0.43 ng/ml after radioligand therapy

Figure 1:  Patient number 8: <sup>177</sup>Lutetium-prostate-specific membrane antigen whole-body scans in anterior and posterior projection 24 h after injection of diagnostic dose of 185 MBq (a) and therapeutic dose of 6 GBq (b) of <sup>177</sup>Lutetium-prostate-specific membrane antigen, which are comparable in showing multiple lymph node involvement in the abdomen and pelvic cavity. He is a 78-year-old man who had undergone radical prostatectomy and radiation therapy. He could not afford second-line hormone therapy (abiraterone and enzalutamide) and was not a suitable candidate for chemotherapy. The baseline prostate-specific antigen = 3.1 ng/ml declined to 0.43 ng/ml after radioligand therapy